In certain embodiments, any controlled-release otic formulation described herein increases the exposure time of an active agent and decreases the C max in otic fluids (e.g., endolymph and/or perilymph) by about 40%, about 30%, about 20%, or about 10%, compared to a formulation that is not a controlled-release otic formulation
After the Tween 80/Span 20 ratio was optimized, the molar ratio of IPM to the Tween 80/Span 20 mixture was varied as 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, and 9:1 to select the optimal ratio of IPM to the surfactant mixture
Short human follow-up: small exploratory reports cannot reveal reliable long-term safety
Product Specifications & Chemical Structure Product Overview: The BPC-157 Molecular Composition Cellular Mechanisms & Research Applications The primary utility of the BPC-157 compound relies entirely on its unique molecular stability and its interaction with cellular growth receptors
Vitamin B12 injections as a bonus or supplement
